Investigating novel pharmacological strategies for treatment-resistant depression: focus on new mechanisms and approaches

Understanding the multiple pathophysiological mechanisms involved in treatment-resistant depression (TRD) may improve treatment by enabling a more personalized approach. Esketamine has been approved for TRD, and novel drugs with rapid antidepressant actions, such as psilocybin and buprenorphine, are being investigated as potential therapies. Technological advances like omics approaches have expanded knowledge of the molecular and genetic underpinnings of TRD and could open new avenues for studying glial-mediated mechanisms, including their interactions with neurons, as therapeutic targets.

Study at a glance

Abstract

The understanding of the multiple pathophysiological mechanisms involved in TRD may add further value to the effective treatment, contributing to a more personalized approach. Esketamine was approved for the treatment of TRD and novel drugs with rapid antidepressant actions such as psilocybin and buprenorphine have also been investigated as potential therapeutic strategies. Over the past decades, technological advances such as omics approaches have broadened our knowledge regarding molecular and genetic underpinnings of complex conditions like TRD. Omics approaches could open new avenues for investigating glial-mediated mechanisms, including their crosstalk with neurons, as therapeutic targets in TRD.